Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCB Insights

Investor Interview: Primary on Casap

View original at cbinsights.com
CB Insights - Enterprise Ai Title: Investor Interview: Primary on Casap Date: 2026-08-03 20:07 Source: https://www.cbinsights.com/research/investor-interview-casap/ <h4>Emily Man, Partner at <a href="https://app.cbinsights.com/profiles/i/eQd?tab=overview">Primary</a>, tells CB Insights how they view <a href="https://ap…
Opening lines of the source · CB Insights · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Shanti and Sayisi both experienced the pain points of disputes firsthand at their respective large fintech companies, and saw the amount of internal effort and organizational work required to solve those challenges even with a strong engineering team.

    60% confidence
  • Primary was excited about Shanti and Sayisi because of their backgrounds and the opportunity they were considering pursuing.

    60% confidence
  • Feedback from colleagues and people who had worked with Shanti and Sayisi was resoundingly clear that they were two exceptional builders passionate about starting their own company and solving problems they had personally seen.

    60% confidence
  • Primary met Shanti and Sayisi before they had left their respective companies at Robin Hood and Chime, while they were still ideating in the space.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com